Leukocyte Surface Antigen CD47 – Pipeline Review, H2 2019

Global Markets Direct’s, 'Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)- Pipeline Review, H2 2019’, provides in depth analysis on Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Infectious Disease and Metabolic Disorders under development targeting Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

– The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects

– The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Abpro Corp

ALX Oncology Inc

Arch Oncology Inc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biocad

Bristol-Myers Squibb Co

EpicentRx Inc

Forty Seven Inc

GeneScience Pharmaceuticals Co Ltd

GigaGen Inc

Hummingbird Bioscience Pte Ltd

I-Mab Biopharma Co Ltd

ImmuneOncia Therapeutics LLC

ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

Innovent Biologics Inc

Jiangsu Hengrui Medicine Co Ltd

KAHR medical Ltd

LynkCell Inc

MesaGen LLC

NovImmune SA

Opsyon

Paradigm Shift Therapeutics LLC

Phanes Therapeutics Inc

PharmAbcine Inc

Shanghai Henlius Biotech Inc

Sorrento Therapeutics Inc

Surface Oncology Inc

Synthon Holdings BV

TOT Biopharm Co Ltd

Trillium Therapeutics Inc

Waterstone Hanxbio Pty Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development

Abpro Corp

ALX Oncology Inc

Arch Oncology Inc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biocad

Bristol-Myers Squibb Co

EpicentRx Inc

Forty Seven Inc

GeneScience Pharmaceuticals Co Ltd

GigaGen Inc

Hummingbird Bioscience Pte Ltd

I-Mab Biopharma Co Ltd

ImmuneOncia Therapeutics LLC

ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

Innovent Biologics Inc

Jiangsu Hengrui Medicine Co Ltd

KAHR medical Ltd

LynkCell Inc

MesaGen LLC

NovImmune SA

Opsyon

Paradigm Shift Therapeutics LLC

Phanes Therapeutics Inc

PharmAbcine Inc

Shanghai Henlius Biotech Inc

Sorrento Therapeutics Inc

Surface Oncology Inc

Synthon Holdings BV

TOT Biopharm Co Ltd

Trillium Therapeutics Inc

Waterstone Hanxbio Pty Ltd

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles

ABP-160 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALX-148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Appendix

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1)

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Abpro Corp, H2 2019

Pipeline by ALX Oncology Inc, H2 2019

Pipeline by Arch Oncology Inc, H2 2019

Pipeline by Aurigene Discovery Technologies Ltd, H2 2019

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2019

Pipeline by Biocad, H2 2019

Pipeline by Bristol-Myers Squibb Co, H2 2019

Pipeline by EpicentRx Inc, H2 2019

Pipeline by Forty Seven Inc, H2 2019

Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2019

Pipeline by GigaGen Inc, H2 2019

Pipeline by Hummingbird Bioscience Pte Ltd, H2 2019

Pipeline by I-Mab Biopharma Co Ltd, H2 2019

Pipeline by ImmuneOncia Therapeutics LLC, H2 2019

Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, H2 2019

Pipeline by Innovent Biologics Inc, H2 2019

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019

Pipeline by KAHR medical Ltd, H2 2019

Pipeline by LynkCell Inc, H2 2019

Pipeline by MesaGen LLC, H2 2019

Pipeline by NovImmune SA, H2 2019

Pipeline by Opsyon, H2 2019

Pipeline by Paradigm Shift Therapeutics LLC, H2 2019

Pipeline by Phanes Therapeutics Inc, H2 2019

Pipeline by PharmAbcine Inc, H2 2019

Pipeline by Shanghai Henlius Biotech Inc, H2 2019

Pipeline by Sorrento Therapeutics Inc, H2 2019

Pipeline by Surface Oncology Inc, H2 2019

Pipeline by Synthon Holdings BV, H2 2019

Pipeline by TOT Biopharm Co Ltd, H2 2019

Pipeline by Trillium Therapeutics Inc, H2 2019

Pipeline by Waterstone Hanxbio Pty Ltd, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports